Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2759481 | 0.91 | TDP1 (0.57) | ALDH1A1POLB | |
| SCHEMBL8588760 | 0.86 | ACHE (0.60) | ALDH1A1GAALMNAKDM4EHPGD | |
| SCHEMBL24925717 | 0.86 | GAA (0.62) | ALDH1A1GAALMNAKDM4EHPGD | |
| SCHEMBL22861473 | 0.81 | ALDH1A1 (0.64) | ALDH1A1GAALMNAKDM4EHPGD | |
| SCHEMBL8588183 | 0.81 | ACHE (0.54) | ALDH1A1 | |
| SCHEMBL22281957 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GAALMNAKDM4EHPGD | |
| SCHEMBL39968 | 0.81 | LMNA (0.58) | ALDH1A1GAALMNAKDM4EHPGD | |
| SCHEMBL7888060 | 0.81 | ALDH1A1 (0.50) | ALDH1A1GAALMNAKDM4EHPGD | |
| SCHEMBL76649 | 0.80 | GAA (0.68) | ALDH1A1GAALMNAKDM4EPOLB | |
| SCHEMBL22890926 | 0.80 | ALDH1A1 (0.63) | ALDH1A1GAALMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885GAA 2390/4885LMNA 4444/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885GAA 2390/4885LMNA 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.